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Jerry M. Wells4, Taia M. B. Rezende  1,6,8, Renko de Vries  2 & octávio L. franco1,3,7 ✉
the spread of multi-drug resistance and the slow pace at which antibiotics come onto the market 
are undermining our ability to treat human infections, leading to high mortality rates. Aiming to 
overcome this global crisis, antimicrobial peptides are considered promising alternatives to counter 
bacterial infections with multi-drug resistant bacteria. the cathelicidins comprise a well-studied class 
of AMPs whose members have been used as model molecules for sequence modifications, aiming 
at enhanced biological activities and stability, along with reduced toxic effects on mammalian cells. 
Here, we describe the antimicrobial activities, modes of action and structural characterization of two 
novel cathelicidin-like peptides, named BotrAMP14 and CrotAMP14, which were re-designed from 
snake batroxicidin and crotalicidin, respectively. BotrAMP14 and CrotAMP14 showed broad-spectrum 
antibacterial activity against susceptible microorganisms and clinical isolates with minimal inhibitory 
concentrations ranging from 2–35.1 μM. Moreover, both peptides had low cytotoxicity against Caco-2 
cells in vitro. In addition, in vivo toxicity against Galleria mellonella moth larvae revealed that both 
peptides led to>76% larval survival after 144 h. Microscopy studies suggest that BotrAMP14 and 
CrotAMP14 destabilize E. coli membranes. Furthermore, circular dichroism and molecular dynamics 
simulations indicate that, in a membrane-like environment, both peptides adopt α-helical structures 
that interact with bilayer phospholipids through hydrogen bonds and electrostatic interaction. Thus, 
we concluded that BotrAMP14 and CrotAMP14 are helical membrane active peptides, with similar 
antibacterial properties but lower cytotoxicity than the larger parent peptides batroxicidin and 
crotalicidin, having advantages for drug development strategies.
The discovery of penicillin and streptomycin during the golden age of antibiotics heralded a revolution in med-
ical treatment of infections. Nevertheless, the spread of antibiotic resistance has made these antibiotics ineffec-
tive against many common pathogens1. The overuse and/or misuse of antibiotics results in microbial resistance 
through a variety of mechanisms1. Horizontal transfer of resistance determinants within and between species, and 
/or DNA mutations, has led to the emergence of pathogens resistant to multiple drugs2, reducing our capacity to 
treat multi-drug resistant bacterial infections1. Consequently, research on the development of new strategies to 
control antibiotic-resistance has intensified, including the usage of antimicrobial peptides (AMPs), which repre-
sent one of the oldest innate defense mechanisms in living organisms3–5. The composition and biological effects 
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of AMPs found in nature are diverse. AMPs can range in length from 2–50 amino acid residues, and have a great 
diversity of amino acid composition, structure and size3. These compounds were initially studied because of 
their antimicrobial activity, and it was discovered that they possess a rich spectrum of other biological activities, 
including immunomodulatory actions, wound healing and anticancer properties5–9.
AMPs are being considered as therapeutic agents but have a number of limitations, including serum stability, 
bioavailability, cytotoxicity and size, as well as the cost of peptide synthesis10. The rational (re)design of AMPs 
provides further possibilities to enhance their activity, increase stability, as well as specificity, and reduce their 
size. For example, sequence modifications of natural peptides can increase peptide helicity, hydrophobic moment 
and net charge, while reducing hydrophobicity11, all factors which are reported as crucial for cationic AMPs, 
including cecropins, magainin, melittin and the cathelicidins12. Moreover, the structural arrangements adopted 
by AMPs can be partially related to their amphipathic nature, which makes them able to present varied structures, 
including α-helices, β-sheets, coils or a mixture of all, which are important for interactions with their bacterial 
targets13.
Among AMP classes, cathelicidin related antimicrobial peptides (CRAMPs) are produced by diverse verte-
brates, including mammals and snakes, and have been widely studied14. Cathelicidins are often expressed and 
secreted by epithelial cells lining animal glands or mucosa. The N-terminal domain is a highly conserved region 
composed of its signal peptide and the cathelin domain. In contrast, the CRAMP C-terminal domain, contain-
ing the mature peptide sequence, is highly variable in length and sequence, both interspecies and intraspecies15. 
Reptilian CRAMPs, particularly those from lizards and snakes, show broad-spectrum antimicrobial activity 
against a large number of bacteria, fungi and viruses16. In addition to their antimicrobial effect, cathelicidins have 
been reported to have multiple activities, including the activation of immune cells, promotion of cell proliferation, 
cell migration, cell survival, cytokine release, angiogenesis, chemotaxis, and wound healing, thus clearly repre-
senting a promising class of therapeutic agents16.
The cathelicidin AMPs originate from several sources, including snake venom14, which has been widely 
studied for its antimicrobial properties13,17. In the present study, two cathelicidin peptides (batroxicidin and 
crotalicidin) have been chosen for the physicochemical-guided design of improved variants. Batroxicidin and 
crotalicidin18 were identified in the South American pit vipers Bothrops atrox and Crotalus durissus terrificus. 
These peptides contain 34 amino acid residues and have exerted pronounced antimicrobial activity against diverse 
bacteria, with few haemolytic effects or proinflammatory effects on RAW 264.7 cells19. These properties suggest 
that batroxicidin and crotalicidin are promising candidates for antibacterial therapy. Snake AMPs, such as the 
snake cathelicidin NA-CATH and its smaller derivative (ATRA1), have achieved similar therapeutic potential20,21, 
suggesting it would be worthwhile to characterize these smaller batroxicidin and crotalicidin variants.
This paper describes two new synthetic peptides (BotrAMP14 and CrotAMP14) derived from the viperi-
cidins, batroxicidin and crotalicidin18, which were generated by a physicochemical-guided design strategy aiming 
to reduce their size, as well as preserve or improve the antibacterial properties and low toxicity of their par-
ent peptides. In addition, the modes of action of both variants on E. coli cells were also evaluated, and compu-
tational and experimental structural studies were performed in different biomimetic conditions to investigate 
structure-function relationships in these two peptides.
Material and Methods
peptide re-design. Initially, the cathelicidin template sequences (batroxicidin and crotalicidin) were col-
lected from the Uniprot knowledgebase (https://www.uniprot.org). The physicochemical characteristics for 
the templates and designed peptides, including pI, hydrophobicity, hydrophobic moment and net-charge, were 
obtained by submitting the sequences to the compute_pi algorithm22 (http://web.expasy.org/compute_pi/) and 
the Heliquest server (http://heliquest.ipmc.cnrs.fr/) helical-wheel projections23.
peptide synthesis and preparation. The peptides were purchased from Peptides 2.0 (USA) at a purity 
of >95%. The molecular mass for the peptides was confirmed using Matrix Assisted Laser Desorption Ionization 
– Time of Flight (MALDI-ToF) on a mass spectrometer Ultraflex MALDI-TOF III (Bruker Daltonics)24. The con-
centration of the designed peptides was determined using measurements of absorbance at 205, 215 and 225 nm as 
described by Niebergall and co-workers25.
In vitro antimicrobial assays. Minimal inhibitory concentration (MIC) and minimal bactericidal con-
centration (MBC) experiments were performed for the ATCC and Clinical Isolated strains of E. coli 25922 K. 
pneumoniae 13822, and S. aureus 25923. The antimicrobial activities of all the peptides were tested as previously 
described with minor modifications26. Briefly, Mueller-Hinton (Himedia) broth was used to grow the strains over-
night at 37 °C. MIC measurements were performed using 1 × 105 CFU.mL−1 and serial dilution of the peptides 
BotrAMP14 and CrotAMP14 starting at 50 µM. The MIC (100% inhibitory concentration) was determined after 
24 h of incubation at 37 °C. The absorbance was measured in a 96-well microplate at 600 nm. Bacteria cultured 
only in MHB and containing the antibiotics (chloramphenicol, gentamicin and imipenem) were used as negative 
and positive control, respectively. MBCs were determined by plating out 10 µL of the contents of the wells where 
no bacterial growth was observed on MH agar plates. MBC was recorded as the lowest concentration at which no 
colonies were observed after 24 h incubation at 37 °C. All the measurements were performed in triplicate.
neutral-red (nR) in vitro toxicity assay. Toxicity of the peptides on Caco-2 cells, at increasing peptide 
concentrations, was determined using a neutral-red (NR) assay as described previously27. After overnight incu-
bation of Caco-2 cells with the peptides BotrAMP14 and CrotAMP14 at concentrations from 2–35 µM, 10 μL of a 
33 µg.mL−1 NR solution was added to the wells containing the peptide-incubated cells. After 3 h of incubation, the 
supernatant was removed, and the cells were washed with phosphate buffer saline (PBS). Next, 150 μL of 1% acetic 
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acid-50% ethanol was added and shaken for 10 min at room temperature. Finally, the absorbance was measured 
at 540 nm and 690 nm (background absorbance) using a SpectraMax M5 microplate reader (Molecular Devices). 
Readings were expressed as NR uptake relative to the uptake of the cells exposed to the negative control (medium 
or DMSO). All the measurements were performed in triplicate.
Galleria mellonella in vivo toxicity assay. In vivo toxicity was assayed using Galleria mellonella larvae28 
in their final instar stage. The larvae were purchased (UK Waxworms Ltd, Sheffield, UK), and acclimatized in the 
dark at 15 °C, and used within 14 days. Only larvae weighing between 0.2 and 0.3 g were used for experiments. 
Larvae were injected with 20 μL of BotrAMP14 and CrotAMP14 peptide solutions, or controls in the left posterior 
proleg using Terumo Myjector 29 G insulin syringes (VWR International). Two negative control groups were 
included in every experiment; one group was not injected to control for background larval mortality (no manip-
ulation control) and the other group (uninfected control) was injected with PBS to control for the possible effect 
of physical trauma on mortality. After injection, larvae were acclimatized in Petri dishes in the dark at 37 °C with 
5% CO2 for up to 144 h post-inoculation and inspected every 24 h for survival. For each sample (non-manipulated 
control, water control, peptides) fifteen randomly chosen larvae were used. The peptide concentration was 10 mg.
kg−1 of body weight. The data were expressed as % larval survival of the survival of the uninfected control. All the 
measurements were performed in triplicate.
circular Dichroism. Circular dichroism (CD) spectra were obtained using a Jasco-715 spectro-polarimeter 
equipped with a Peltier element for temperature control. CD spectra were obtained in the far-UV range, from 
200 to 260 nm using a quartz cuvette with 0.1 cm optical path. An averaging of 20 single scans was obtained for 
the peptide concentration of 110 μM, for demi water, 10 mM potassium phosphate buffered saline at pH 7.4, and 
30 mM of sodium dodecyl sulphate (SDS). All the spectra were fitted using the CONTIN algorithm as imple-
mented in the DICHROWEB29–32 webserver, using the data basis set #7 for a quantitative interpretation of the 
spectra in terms of a percentage of α-helical structure.
Molecular modeling. Initially, BLASTp33 was performed in order to find the best template structures for 
the molecular modeling of BrotAMP and CrotAMP. Further, 100 theoretical three-dimensional models were 
constructed using Modeller v. 9.1233, based on the nuclear magnetic resonance (NMR) structure of a crotalicidin 
isolated from venom of the rattlesnake (Crotallus durissus) (PDB code: 2MWT)18. The lowest free-energy theoret-
ical models (DOPE score) for both peptides were then selected and used for validation procedures according to 
their fold (ProSA-web)34 and stereochemistry (PROCHECK)35. Structure visualization was performed in PyMOL 
(http://www.pymol.org).
Molecular dynamics in water and SDS micelles. Molecular dynamics (MD) simulations for 
BotrAMP14 and CrotAMP14 were initially carried out in contact with an SDS micelle, according to Cardoso 
et al.36. The simulations were performed using the CHARMM36 force field from the computational package 
GROMACS v.5.0.437. MD simulations in SDS were carried out in dodecahedron boxes, where both peptides 
were put in contact with SDS micelles constituted of 100 detergents. SDS micelles were built, and their topologies 
generated using the CHARM-GUI server24. Chloride ions were added to neutralize the systems’ charge in both 
simulations. The simulations were performed under 0.15 M NaCl ionic strength. Geometry of water molecules 
was constrained using the SETTLE algorithm38. Moreover, the LINCS algorithm39 was used to link all the atom 
bond lengths. Particle Mesh Ewald (PME)40 was used for electrostatic corrections with a radius cut-off of 1.4 nm 
to minimize the computational simulation time. The same radius cut-off was used for van der Waals interactions. 
The list of neighbors of each atom was updated every 10 simulation steps of 2 fs each. The steepest descent algo-
rithm (50,000 steps) was applied for energy minimization. The systems underwent a normalization of tempera-
ture and pressure to 310 K and 1 bar using the velocity rescaling thermostat (NVT)41 and the Parrinello-Rahman 
barostat (NPT)42, respectively, for 100 ps. The systems with minimized energy and balanced temperature and 
pressure were submitted to MD simulations for 800 ns. MD simulations were analyzed by means of root mean 
square deviation (RMSD). Moreover, peptide-SDS atomic interactions were measured on PyMOL v. 1.8 (The 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC).
Scanning electronic microscope. Scanning electronic microscopy (SEM) was performed by the adher-
ence of bacteria to Poly-L-Lysine-coated slides. Prior to SEM analysis, E. coli ATCC 25922 was grown in MHB 
overnight at 37 °C, and the concentration of 1 × 105 CFU.mL−1. The bacterial cultures were centrifuged, and 
phosphate buffer was used to replace the MHB. The bacterial culture was increased by adding 8 µM and 2 µM for 
BotrAMP14 and CrotAMP14, respectively, for 5, 30 and 60 min of incubation. For control group, E.coli ATCC 
25922 was used without peptides (time 0). Samples for SEM were prepared by leaving microscope slides coated 
with poly-L-lysine in 10 mL suspension of bacteria incubated with the peptides and allowing them to settle and 
adhere to the slides. After 60 min incubation at RT, the bacteria were fixed using 2.5% glutaraldehyde in phos-
phate buffer. Finally, water was removed using critical point drying: first, the samples were immersed in a graded 
series of increasing ethanol: 25%, 50%, 75%, and two times at 100% each for 10 min. This was followed by trans-
ferring the samples to absolute ethanol, and by critical point drying.
Results and Discussion
Rational design of batroxicidin and crotalicidin variants. The rational (re)design of AMPs to tune 
amphipathicity, degree of helicity, charge, etc.43, can be used to further improve their usefulness as future anti-
microbial medicines. We therefore present two novel AMPs derived from snake cathelicidins. Previously, Falcao 
and colleagues18 reported the discovery of two vipericidins, named crotalicidin and batroxicidin, with very sim-
ilar sequences and high antimicrobial capacity. Subsequently, Falcao and coworkers44 showed that just a small 
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fragment of the C-terminal region of crotalicidin (fragment 15–34), named Ctn [15–34], was highly active against 
diverse microorganisms; whereas the N-terminal sequence showed low antimicrobial activity. We therefore used 
the peptide Ctn [15–34] as template sequence for the generation of CrotAMP14. Following the same rationale 
used for the peptide crotalicidin, where only its C-terminal region has been described as active against microor-
ganisms, the C-terminal region of the peptide batroxicidin (fragment 15-34), named here as Btn [15-34], was also 
used as a template for the generation of another peptide called BotrAMP14.
BotrAMP14 and CrotAMP14 are 14-amino acid peptides derived from the cathelicidin subsequences: Btn[15-
34] (15KKRVKKFFRKPRVIGVTFPF34) from batroxicidin; and Ctn[15-34] (15KKRLKKIFKKPMVIGVTIPF34) 
from crotalicidin, respectively (Fig. 1A). Initially, the parent sequences were mapped into a helical wheel dia-
gram23 (Fig. 1B) to identify the cationic and hydrophobic faces of Btn[15-34] and Ctn[15-34] when folded into 
an α-helix. Based on these diagrams, a series of modifications in Btn[15-34] and Ctn[15-34] were carried out to 
reduce their size and enhanced helical amphipathicity, thus generating BotrAMP14 (KRWKKFFRKVIKFF-NH2) 
and CrotAMP14 (KRLKKIFKKMIKIF-NH2). The aim was to exclude amino acid residues not favorable for the 
electrostatic surface, while maintaining an alternation between positively charged and hydrophobic residues. The 
amino acid residues K1, V4, P11, R12, G15, V16, T17 and P19 in Btn[15-34] were removed from BotrAMP14, followed by 
the addition of tryptophan and lysine residues at position 3 and 12, respectively. Similarly, the residues K1, P11, V13, 
G15, V16, T17 and P19 in Ctn[15-34] were removed from CrotAMP14 and a lysine residue was added at position 12.
The resulting physicochemical changes in BotrAMP14 and CrotAMP14 in comparison to their parent 
sequences are summarized in Table 1. Both peptides were designed focusing on maintaining the high net charge 
of the cathelicidins’ parental sequences, alongside an increased hydrophobic moment and, mainly, the reduction 
of the parental sequence lengths. In a previous study developed by our group, we demonstrated that the cationic 
subsequence Ctn[15-34] can be inactivated through the insertion of a negatively charged propeptide sequence, 
as a potential prodrug strategy45. These peptide inactivation strategies may also be used with BotrAMP14 and 
CrotAMP14 peptides, as their small size and cationic properties were preserved.
Figure 1. (A) - Domain structure of crotalicidins in general followed by the sequence of the natural occurring 
vipericidins (batroxicidin and crotalicidin), the sequence of the intermediate peptides (Btn[15-34] and Ctn[15-
34]) and the rationally designed analogues BotrAMP14 and CrotAMP14. The green letters represent the 
original amino acid sequence. The black letters represent the discarded amino acid. The red letters represent 
hydrophobic amino acids included, and the blue letters represent the cationic amino acids included. B - Helical-
wheel projections for the peptide precursors batroxicidin, crotalicidin, Btn[15-34] and Ctn[15-34], and the 
rational designed BotrAMP14 and CrotAMP14 (B).
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Cationic AMPs from several classes (cathelicidins, defensins and magainins), are commonly modified using 
rational design strategies, which allow a shorter motif to be obtained, decreasing the cost of producing synthetic 
peptides for therapeutic applications43. In addition, the removal of specific residues with undesired properties 
may also produce peptide analogues with lower toxicity and immunostimulatory activities43. In the present work, 
the amino acid Lys (K12) was inserted in both redesigned variants (BotrAMP14 and CrotAMP14) with the aim of 
boosting electrostatic interactions with bacterial membranes and promoting antibacterial activity. Furthermore, 
studies have shown that lysine-rich peptides have reduced toxicity against eukaryotic cells46. The Trp (W3) was 
inserted in BotrAMP14 because of its ability to arrange itself more deeply into the bacterial membranes, present-
ing a distinct preference for the interfacial region of lipid bilayers47. Therefore we expected BotrAMP14 to disrupt 
the bacterial cell membranes more efficiently47. Overall, these amino acids modifications interfered at the helical 
wheel diagram for BotrAMP14 and CrotAMP14, resulting in clear cationic and hydrophobic residues distribution 
along the peptide sequence, thus favoring the amphipathicity (Table 1 and Fig. 1B).
Antibacterial properties of BotrAMP14 and CrotAMP14. The antibacterial activity of the BotrAMP14 
and CrotAMP14 peptides, as well as that of the parental template peptides Btn [15-34] and Ctn [15-34], was eval-
uated against several bacteria, including Gram-negative, Gram-positive susceptible strains, and resistant strains. 
As shown in Table 2, BotrAMP14 and CrotAMP14 exhibited a pronounced activity against both susceptible bac-
teria and clinical isolates. BotrAMP14 presented a stronger activity as compared to the parental Btn [15-34] for 
all strains tested (Table 2). For CrotAMP14 we found the same activity as for the parental peptide Ctn [15-34] for 
Gram-negative strains (except for K. pneumoniae CI 1445333), and improved activity against the Gram-positive 
strains.
The efficient antibacterial activity described here for the designed peptides BotrAMP14 and CrotAMP14 is 
consistent with previous works regarding the precursor CRAMPs18,44,45. Regarding antimicrobial activity, the 
higher MICs observed for the Gram-positive bacteria than for the Gram-negative bacteria tested indicate that 
both redesigned peptides possess a differential affinity for these types of bacterial membranes. By reducing the 
number of amino acid residues and increasing hydrophobic moment, the redesigned peptides had a higher 
MIC for the Gram-positive bacterium S. aureus than Gram-negative bacteria. This feature may be related to 
the increased helicity of the redesigned peptides BotrAMP14 and CrotAMP14 compared to the parental pep-
tides. The propensity to form structures in amphipathic α-helices in membrane-mimicking membrane envi-
ronments has been demonstrated in several studies as an essential factor for the disruptive activity of AMPs48. 
More recently, a smaller derivative of cathelicidin KP36, designated AMP (RN15), also demonstrated promis-
ing activity, mostly against Bacillus bacteria, and low hemolytic and cytotoxicity against dermal human dermal 
fibroblasts49. However, for Gram-negative strains, a slight increase of BotrAMP14 over the parental Btn [16-34] 
was observed. This increase may be related to the tryptophan residue presence, which could lead to an increase 
in membrane/peptide interaction due to tryptophan insertion into the interfacial region of the phospholipid 
bilayer47. This increase was not observed for CrotAMP14 peptide, which maintained the overall parental activ-
ity. Ultimately, the bacterial cytoplasmic membrane lipid composition seems essential for AMPs’ mechanism of 
action. Generally, it is constituted by zwitterionic lipid phosphatidylethanolamine (PE), and anionic lipids phos-
phatidylglycerol (PG) and cardiolipin (CL), which are essential for membrane organization. The lipid composi-
tion differs from one species to another. Usually Gram-positive bacteria present a high anionic lipid (PG and CL) 
amount, which may favor electrostatic interactions. Gram-negative bacteria show higher PE content in compar-
ison to Gram-positive strains50. Such features could explain the higher increased activity against Gram-positive 
bacteria for the redesigned peptides over parental.
Structural analyses. To elucidate the secondary structure of BotrAMP14 and CrotAMP14, CD spectros-
copy, molecular modeling and dynamics simulations were carried out under different experimental conditions. 
CD spectra were acquired in demi-water, 10 mM potassium phosphate buffer at pH 7.4 and in 30 mM SDS, 
and they are shown in Fig. 2. A qualitative comparison with typical CD spectra illustrates that BotrAMP14 and 
CrotAMP14 spectra are characteristic of predominantly random coil configurations in demi-water and in 10 mM 
potassium phosphate buffer (Fig. 2A,B). In contrast, CD spectra of BotrAMP14 and CrotAMP14 indicated sub-
stantial α-helical configuration in a membrane-like environment (SDS) (Fig. 2C). For a more quantitative assess-
ment, we used the CONTIN algorithm to fit the CD spectrum and extract percentages of the α-helical secondary 
Peptides Residues
Net chargea 
(pH7) pIb Hydrophobicityc<H>
Hydrophobic 
momentc<μH> Molecular mass
Batroxicidin 34 +16 12.50 0.207 0.473 4258.29
Crotalicidin 34 +16 12.09 0.263 0.440 4151.33
Btn[15-34] 20 +9 12.32 0.317 0.306 2478.08
Ctn[15-34] 20 +8 11.43 0.455 0.311 2371.07
BotrAMP14 14 +8 12.04 0.390 0.888 1957.46
CrotAMP14 14 +8 11.43 0.354 0.849 1820.43
Table 1. Physicochemical properties of BotrAMP14, CrotAMP14 and their parent peptides. aDetermined 
for C-terminal amidated (NH2) peptides; bDetermined by the compute_pi algorithm (http://web.expasy.org/
compute_pi/); cDetermined by the Heliquest server (http://heliquest.ipmc.cnrs.fr/).
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structure of the peptides (2A-B). The results show BotrAMP14 has an estimated percentages of random coil 
structure in demi water and 10 mM potassium phosphate buffer of ~38% and ~61%, respectively.
For CrotAMP14, the estimated percentages of random coil were very similar in demi-water and buffer 
(i.e. 48% and ~66% respectively). However, the dominant α-helical content of secondary structure in 30 mM 
SDS was ~65% and ~69%, respectively, for BotrAMP14 and CrotAMP14. Similarly, Chen and cowork-
ers51 also demonstrated that the smaller oligopeptide of 15 amino acid residues (1VKRFKKFFRKLKKSV15) 
derived from the cathelicidin BF-30 (Bf-CRAMP), revealing that an oligopeptide of 15 amino acid residues 
(1VKRFKKFFRKLKKSV15) maintained its minimal α-helical structure required for an antimicrobial activity. 
Another study on cathelicidins focused on the use of short synthetic peptides of sequences incorporated into 
Ophiophagus hannah peptides (Oh-CRAMP and Oh-CATH) and distinct antimicrobial activity and hemolysis 
were demonstrated relative to human erythrocytes in comparison with their original parent sequences52.
MD simulations were performed for similar conditions as those used in the CD experiments. MD simula-
tions in the presence of SDS micelles showed that the SDS clearly promoted α-helical conformations for both 
BotrAM14 and CrotAMP14 (Fig. 3C,D). Also, supporting the results of the CD experiments, the two peptides dif-
fer in overall helical chemical contents (Fig. 3A,B). According to the RMSD analysis CrotAMP14 showed ~3-fold 
higher deviations (~0.45 nm) in its trajectory when compared to BotrAMP14 (~0.15 nm) (Fig. 3A). This was also 
reflected in the fluctuation per residue observed for these peptides, where higher RMSF values were observed for 
CrotAMP14 (Fig. 3B).
Our SEM results suggest that both BotrAMP14 and CrotAMP14 directly attach to bacterial surfaces and trig-
ger membrane perturbation events in Gram-negative bacteria. Interestingly, as for our simulations in the presence 
of SDS micelles, CrotAMP14 deviated and fluctuated more during the entire simulation (Fig. 3A). A total of 16 
atomic interactions were predicted for the molecular complex BotrAMP14/SDS. These interactions involved the 
residues K1, R2, W3, K4, K5, F6, R8, V10, I11, K12 and F14 in BotrAMP14 (Supplementary Table 1). Furthermore, 13 
interactions were predicted for the complex CrotAMP14/SDS. These interactions involve the residues K1, R2, 
L3, K4, K5, I6, F7, K12 and I13 in CrotAMP14 (Supplementary Table 2). These data clearly indicate the relevance of 
the positively charged residues of both peptides for initial electrostatic and hydrogen bond interactions with the 
sulfate groups of the SDS molecules.
Membrane interaction analyses. Scanning electron microscope (SEM) analysis was performed to clarify 
possible morphological alterations at MIC concentration for BotrAMP14 and CrotAMP14 at different incubation 
times. The high-resolution images showed that both peptides induced similar damage to E. coli ATCC 25922 bac-
terial cells (Fig. 4). At time 0 h (control), no damage in the bacterial cells (Fig. 4A,B) was observed. However, after 
5 min of exposure to the peptides, bacterial outer membrane damage, including holes and fissures, was clearly 
visible (Fig. 4C,D). The number of these “holes” increased after 30 min incubation (Fig. 4E,F). After 1 h of incuba-
tion larger-scale damage to the cells was apparent (Fig. 4G,H). The results achieved by SEM corroborate the MD 
Microorganisms Gram
Btn [15-34] Ctn [15-34] BotrAMP14 CrotAMP14 Gentamicin Imipenem Chloramphenicol Polimyxin B
Micromole (μM)
MIC (MBC)
E. coli ATCC 25922 — 6.2 (>50) 3.1 (25) 3.1 (50) 3.1 (25) 0,03 (1,5) ** 6.2 (6.2) 0,03 (1.5)
E.coli KpC+ 1812446 — 3.1 (12.5) 1.5 (6.2) 1.5 (3.1) 1.5 (3.1) ** 12.5 (>50) ** **
K. pneumoniae ATCC 
13822 — 12.5 (50) 6.2 (12.5) 6.2 (6.2) 6.2 (6.2) 0.03 (1.5) ** ** **
K. pneumoniae CI 
1445333 — >50 (>50) 6.2 (25) 6.2 (>50) 12.5 (>50) 6.2 (12.5) ** ** **
S. aureus ATCC 25923 + >50 (>50) >50 (>50) 12.5 (50) 12.5 (50) 0.03 (1.5) ** ** **
S. aureus CI + 25 (>50) 25 (>50) 3.1 (>50) 3.1 (>50) 0.03 (1.5) ** ** **
Table 2. Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of the 
redesigned peptides, and the parental peptides against susceptible bacteria and clinical isolate strains.
Figure 2. CD spectra of the peptides BotrAMP14 (red) and CrotAMP14 (Blue). Residue molar ellipticity [q] in 
deg.cm2 /dmol−1 is plotted versus the wavelength l in nm. Measurements were done at a peptide concentration 
of 0.2 mg.mL−1 in demi water (A) 10 mM K2HPO4 50 mM Na2SO4 buffer, pH 7.4 (B) and 30 mM SDS (C).
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simulations. The peptide/membrane interactions using SDS micelles were used to check the interaction between 
the peptides under membrane-mimicking conditions, indicating that peptide/membrane interactions in both 
cases are driven by hydrogen bond, hydrophobic interaction, and salt bridge (electrostatic interactions) between 
the BotrAMP14 and CrotAMP14 peptides, and the SDS micelles groups (sulfate and acyl chain). According 
to Pérez-Peinado and coworkers53 cationic and α-helical peptides in crotalicidin and its analogue Ctn [15-34] 
would accumulate and interact with the negative charges on the bacterial surface. The results of flow cytometry 
confirmed that both crotalicidin and Ctn [15-34] permeabilize the bacterial cell membrane in different ways, 
suggesting their precise mechanisms of action differ53. Based on results obtained by Perez-Peinado and cowork-
ers53 we inferred that both the redesigned peptides used in our study can act in a similar way to those described 
for crotalicidin and Ctn [15-34]. Indeed, the peptides BotrAMP14 and CrotAMP14 maintained many of the 
characteristics presented by original peptides (i.e. Btn [15-34] and Ctn [15-34]), even after their reduction in size.
Cytotoxicity of BotrAMP14 and CrotAMP14. To be used as drugs, antibacterial compounds must have 
high selectivity to the pathogens at therapeutic concentrations in the body and must lack cytotoxicity to the host 
cells. Usually, the cytotoxic properties associated with both naturally occurring and rationally designed AMPs 
represent a bottleneck in the treatment of infections using these molecules. In this context, the toxic effects of 
BotrAMP14 and CrotAMP14 on mammalian cells were initially investigated in vitro using Caco-2 cells. Neutral 
red uptake (NRU) assay was used to determine the viability of mammalian Caco-2 cells as a function of peptide 
concentration. We observed that cells incubated with BotrAMP14 showed 100% viability at the maximum con-
centration tested (88 μM (Fig. 5A). At this same concentration, however, the CrotAMP14 peptide was cytotoxic, 
reducing cell viability to 60% (Fig. 5A). Caco-2 cells can be widely used to test the intestinal permeability and 
toxicity for several drugs54. The lack of toxicity of BotrAMP14 and CrotAMP14 against Caco-2 cells is very prom-
ising and can be used for future intestinal permeability assays, since antibiotics may lead to an imbalance of the 
microbiota, which is important when considering the inclusion of new drugs on the market.
Figure 3. MD simulation for BrotAMP14 and CrotAMP14 peptides in the presence of SDS micelles. MD 
simulations were analyzed by determining root mean square deviations (RMSD) (A) and root mean square 
fluctuation (RMSF) (B). The three-dimensional structures of BrotAMP14 (C) and CrotAMP14 (D) were 
visualized after 800 ns of MD simulations, indicating the presence of a higher α-helix content for BrotAMP14 as 
compared with CrotAMP14. White sticks represent selected SDS molecules that are involved in stabilizing the 
peptide secondary structure.
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Toxicity of BotrAMP14 and CrotAMP14 to Galleria mellonela larvae. Infectivity trials and toxicity 
testing in rodents are important requisites for the use of drug candidates in humans. However, trials in rats and 
mice are expensive and there are ethical considerations. G. mellonella (greater wax moth) larvae are a potential 
alternative as they have evolutionarily conserved immunity consisting of both cellular and humoral defenses55. 
In vivo experiments were performed using greater wax moth G. mellonella larvae for a period of 144 h, at a pep-
tide concentration of 10 mg.kg−1 of body weight (Fig. 5B). Survival curves indicated that both BotrAMP14 and 
Figure 4. Scanning electronic microscope (SEM) high-resolution images of E. coli ATCC 25922 in the presence 
of BotrAMP14 (8.1 μM) and CrotAMP14 (2.2 μM) peptides after 0 min (A,B), 5 min (C,D), 30 min (E,F) and 
60 min (G,H) of incubations. Arrows indicate cell damage. Panels A, C, E, and G represent the treatments with 
BotrAMP14. Panels B, D, F, and H represent the treatments with CrotAMP14 peptide.
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CrotAMP14 have low toxicity for the larvae. For BotrAMP14, we observed 86.6% of larval survival after 144 h 
of experiment. The peptide CrotAMP14 was slightly more toxic, resulting in 76.6% larval survival after 144 h 
(Fig. 5B). Latour and coworkers21 showed the antimicrobial activity of peptides derived from Naja atra, composed 
of the ATRA motif, i.e, KR(F/A)KKFFKK(L/P)K, with a trivial toxicity against erythrocytes21. Contrary to what 
was demonstrated here, Wang and coworkers56 showed that derivative crotalicidin EVP50 presented the highest 
toxicity activity against zebrafish larvae in comparison to the original vipericidin sequences. On the other hand, 
other studies performed with analogues/derivatives of cathelicidins reported that these peptides had low toxicity 
and hemolytic activity51.
In conclusion, it was possible to observe that the physicochemical-guided design of BotrAMP14 and 
CrotAMP14 preserved the antibacterial and non-toxic potential of their parent sequences despite their smaller 
size, suggesting the applicability of these variants as new drug candidates. We also concluded that both pep-
tides act on Gram-negative bacteria through a membrane destabilization mechanism, which is mainly driven 
by electrostatic interactions and hydrogen bonding between the N-terminus region of these peptides and ani-
onic membranes, leading to peptide anchoring and insertion. Overall, BotrAMP14 and CrotAMP14 appear 
as suitable candidates for further drug development, especially for the treatment of resistant Gram-negative 
bacteria-associated infections.
Received: 26 June 2019; Accepted: 6 May 2020;
Published: xx xx xxxx
References
 1. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336–343, https://doi.org/10.1038/
nature17042 (2016).
 2. Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74, 417–433, https://doi.org/10.1128/
MMBR.00016-10 (2010).
 3. Ageitos, J. M., Sanchez-Perez, A., Calo-Mata, P. & Villa, T. G. Antimicrobial peptides (AMPs): Ancient compounds that represent 
novel weapons in the fight against bacteria. Biochem. Pharmacol. 133, 117–138, https://doi.org/10.1016/j.bcp.2016.09.018 (2017).
 4. Guani-Guerra, E., Santos-Mendoza, T., Lugo-Reyes, S. O. & Teran, L. M. Antimicrobial peptides: general overview and clinical 
implications in human health and disease. Clin Immunol 135, 1–11, https://doi.org/10.1016/j.clim.2009.12.004 (2010).
 5. Kang, H. K., Kim, C., Seo, C. H. & Park, Y. The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J 
Microbiol 55, 1–12, https://doi.org/10.1007/s12275-017-6452-1 (2017).
 6. Zaiou, M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J Mol Med (Berl) 85, 317–329, 
https://doi.org/10.1007/s00109-006-0143-4 (2007).
 7. Baba, M. S. et al. In vivo antimalarial activity of the endophytic actinobacteria, Streptomyces SUK 10. J Microbiol 53, 847–855, 
https://doi.org/10.1007/s12275-015-5076-6 (2015).
 8. Kim, H. et al. Oral administration of Lactobacillus plantarum lysates attenuates the development of atopic dermatitis lesions in 
mouse models. J Microbiol 53, 47–52, https://doi.org/10.1007/s12275-015-4483-z (2015).
 9. Patil, S. D. et al. Antibacterial potential of a small peptide from Bacillus sp. RPT-0001 and its capping for green synthesis of silver 
nanoparticles. J Microbiol 53, 643–652, https://doi.org/10.1007/s12275-015-4686-3 (2015).
 10. Sun, L., Zheng, C. & Webster, T. J. Self-assembled peptide nanomaterials for biomedical applications: promises and pitfalls. Int J 
Nanomedicine 12, 73–86, https://doi.org/10.2147/IJN.S117501 (2017).
 11. Torres, M. D. T., Sothiselvam, S., Lu, T. K. & de la Fuente-Nunez, C. Peptide Design Principles for Antimicrobial Applications. J. Mol. 
Biol. 431, 3547–3567, https://doi.org/10.1016/j.jmb.2018.12.015 (2019).
 12. Oh, D. et al. Role of the hinge region and the tryptophan residue in the synthetic antimicrobial peptides, cecropin A(1-8)-magainin 
2(1-12) and its analogues, on their antibiotic activities and structures. Biochemistry 39, 11855–11864, https://doi.org/10.1021/
bi000453g (2000).
Figure 5. Toxicity of the peptides BotrAMP14 and CrotAMP14 on Caco-2 cells. In vitro neutral red uptake 
assay using Caco-2 cells. Viability as compared to untreated Caco-2 cells as a function of peptide concentration 
(A). Empty circle: PBS buffer control, filled square: BotrAMP14, filled triangle: CrotAMP14. (B) In vivo toxicity 
of BotrAMP14 and CrotAMP14 on Galleria mellonella larvae represented by percentage of surviving larvae as 
a function of time. Empty circle: H2O control, empty diamond: non-manipulated, filled square: BotrAMP14, 
filled triangle: CrotAMP14. All the experiments were performed in triplicate.
1 0Scientific RepoRtS |         (2020) 10:9127  | https://doi.org/10.1038/s41598-020-66164-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 13. Ramos, R. et al. Wound healing activity of the human antimicrobial peptide LL37. Peptides 32, 1469–1476, https://doi.org/10.1016/j.
peptides.2011.06.005 (2011).
 14. Pazgier, M. et al. Structural and functional analysis of the pro-domain of human cathelicidin, LL-37. Biochemistry 52, 1547–1558, 
https://doi.org/10.1021/bi301008r (2013).
 15. Zanetti, M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol 7, 179–196 (2005).
 16. Perumal Samy, R., Stiles, B. G., Franco, O. L., Sethi, G. & Lim, L. H. K. Animal venoms as antimicrobial agents. Biochem. Pharmacol. 
134, 127–138, https://doi.org/10.1016/j.bcp.2017.03.005 (2017).
 17. Wang, Y. et al. Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics. PLoS One 3, e3217, https://doi.org/10.1371/
journal.pone.0003217 (2008).
 18. Falcao, C. B. et al. Vipericidins: a novel family of cathelicidin-related peptides from the venom gland of South American pit vipers. 
Amino Acids 46, 2561–2571, https://doi.org/10.1007/s00726-014-1801-4 (2014).
 19. Oliveira-Junior, N. G., Freire, M. S., Almeida, J. A., Rezende, T. M. B. & Franco, O. L. Antimicrobial and proinflammatory effects of 
two vipericidins. Cytokine 111, 309–316, https://doi.org/10.1016/j.cyto.2018.09.011 (2018).
 20. Blower, R. J. & Barksdale, S. M. & van Hoek, M. L. Snake Cathelicidin NA-CATH and Smaller Helical Antimicrobial Peptides Are 
Effective against Burkholderia thailandensis. PLoS Negl Trop Dis 9, e0003862, https://doi.org/10.1371/journal.pntd.0003862 (2015).
 21. de Latour, F. A., Amer, L. S., Papanstasiou, E. A., Bishop, B. M. & van Hoek, M. L. Antimicrobial activity of the Naja atra cathelicidin 
and related small peptides. Biochem. Biophys. Res. Commun. 396, 825–830, https://doi.org/10.1016/j.bbrc.2010.04.158 (2010).
 22. Wilkins, M. R. et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112, 531–552, https://doi.
org/10.1385/1-59259-584-7:531 (1999).
 23. Gautier, R., Douguet, D., Antonny, B. & Drin, G. HELIQUEST: a web server to screen sequences with specific alpha-helical 
properties. Bioinformatics 24, 2101–2102, https://doi.org/10.1093/bioinformatics/btn392 (2008).
 24. Wu, E. L. et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 
1997–2004, https://doi.org/10.1002/jcc.23702 (2014).
 25. Niebergall, P. J. & Mattocks, A. M. A note on the use of multiple regression for spectrophotometric assays involving more than one 
component. Drug Stand 28, 61–64 (1960).
 26. Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration 
(MIC) of antimicrobial substances. Nat Protoc 3, 163–175, https://doi.org/10.1038/nprot.2007.521 (2008).
 27. Repetto, G., del Peso, A. & Zurita, J. L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 3, 
1125–1131, https://doi.org/10.1038/nprot.2008.75 (2008).
 28. Velikova, N., Kavanagh, K. & Wells, J. M. Evaluation of Galleria mellonella larvae for studying the virulence of Streptococcus suis. 
BMC Microbiol 16, 291, https://doi.org/10.1186/s12866-016-0905-2 (2016).
 29. Whitmore, L. & Wallace, B. A. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism 
spectroscopic data. Nucleic Acids Res. 32, W668–673, https://doi.org/10.1093/nar/gkh371 (2004).
 30. Whitmore, L. & Wallace, B. A. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference 
databases. Biopolymers 89, 392–400, https://doi.org/10.1002/bip.20853 (2008).
 31. Provencher, S. W. & Glockner, J. Estimation of globular protein secondary structure from circular dichroism. Biochemistry 20, 
33–37, https://doi.org/10.1021/bi00504a006 (1981).
 32. van Stokkum, I. H., Spoelder, H. J., Bloemendal, M., van Grondelle, R. & Groen, F. C. Estimation of protein secondary structure and 
error analysis from circular dichroism spectra. Anal. Biochem. 191, 110–118, https://doi.org/10.1016/0003-2697(90)90396-q (1990).
 33. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815, https://doi.
org/10.1006/jmbi.1993.1626 (1993).
 34. Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of 
proteins. Nucleic Acids Res. 35, W407–410, https://doi.org/10.1093/nar/gkm290 (2007).
 35. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereochemical quality of 
protein structures. J. Appl. Crystallogr. 26, 283–291, https://doi.org/10.1107/s0021889892009944 (1993).
 36. Cardoso, M. H. et al. A polyalanine peptide derived from polar fish with anti-infectious activities. Sci Rep 6, 21385, https://doi.
org/10.1038/srep21385 (2016).
 37. Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to 
supercomputers. SoftwareX 1-2, 19–25, https://doi.org/10.1016/j.softx.2015.06.001 (2015).
 38. Miyamoto, S. & Kollman, P. A. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. 
Chem. 13, 952–962, https://doi.org/10.1002/jcc.540130805 (1992).
 39. Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations. J. Comput. 
Chem. 18, 1463–1472, 10.1002/(sici)1096-987x(199709)18:12<1463::Aid-jcc4>3.0.Co;2-h (1997).
 40. Ewald, P. P. Die Berechnung optischer und elektrostatischer Gitterpotentiale. Annalen der Physik 369, 253–287, https://doi.
org/10.1002/andp.19213690304 (1921).
 41. Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101, https://doi.
org/10.1063/1.2408420 (2007).
 42. Parrinello, M. & Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys. 52, 
7182–7190, https://doi.org/10.1063/1.328693 (1981).
 43. Ong, Z. Y., Wiradharma, N. & Yang, Y. Y. Strategies employed in the design and optimization of synthetic antimicrobial peptide 
amphiphiles with enhanced therapeutic potentials. Adv Drug Deliv Rev 78, 28–45, https://doi.org/10.1016/j.addr.2014.10.013 (2014).
 44. Falcao, C. B. et al. Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial 
and Antitumor Activity. J. Med. Chem. 58, 8553–8563, https://doi.org/10.1021/acs.jmedchem.5b01142 (2015).
 45. Junior, N. G. O. et al. An acidic model pro-peptide affects the secondary structure, membrane interactions and antimicrobial activity 
of a crotalicidin fragment. Sci Rep 8, 11127, https://doi.org/10.1038/s41598-018-29444-0 (2018).
 46. Sato, H. & Feix, J. B. Lysine-enriched cecropin-mellitin antimicrobial peptides with enhanced selectivity. Antimicrob. Agents 
Chemother. 52, 4463–4465, https://doi.org/10.1128/AAC.00810-08 (2008).
 47. Haug, B. E. & Svendsen, J. S. The role of tryptophan in the antibacterial activity of a 15-residue bovine lactoferricin peptide. J. Pept. 
Sci. 7, 190–196, https://doi.org/10.1002/psc.318 (2001).
 48. Takahashi, D., Shukla, S. K., Prakash, O. & Zhang, G. Structural determinants of host defense peptides for antimicrobial activity and 
target cell selectivity. Biochimie 92, 1236–1241, https://doi.org/10.1016/j.biochi.2010.02.023 (2010).
 49. Tankrathok, A. et al. Identification of the first Crocodylus siamensis cathelicidin gene and RN15 peptide derived from cathelin 
domain exhibiting antibacterial activity. Biotechnol. Appl. Biochem. 66, 142–152, https://doi.org/10.1002/bab.1709 (2019).
 50. Epand, R. M. & Epand, R. F. Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim Biophys Acta 
1788, 289–294, https://doi.org/10.1016/j.bbamem.2008.08.023 (2009).
 51. Chen, W. et al. Structure-activity relationships of a snake cathelicidin-related peptide, BF-15. Peptides 32, 2497–2503, https://doi.
org/10.1016/j.peptides.2011.10.005 (2011).
 52. Zhang, Y. et al. Structure-function relationship of king cobra cathelicidin. Peptides 31, 1488–1493, https://doi.org/10.1016/j.
peptides.2010.05.005 (2010).
 53. Perez-Peinado, C. et al. Mechanisms of bacterial membrane permeabilization by crotalicidin (Ctn) and its fragment Ctn(15-34), 
antimicrobial peptides from rattlesnake venom. J. Biol. Chem. 293, 1536–1549, https://doi.org/10.1074/jbc.RA117.000125 (2018).
1 1Scientific RepoRtS |         (2020) 10:9127  | https://doi.org/10.1038/s41598-020-66164-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 54. Sambuy, Y. et al. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell 
functional characteristics. Cell Biol Toxicol 21, 1–26, https://doi.org/10.1007/s10565-005-0085-6 (2005).
 55. Lionakis, M. S. Drosophila and Galleria insect model hosts: new tools for the study of fungal virulence, pharmacology and 
immunology. Virulence 2, 521–527, https://doi.org/10.4161/viru.2.6.18520 (2011).
 56. Wang, L. et al. Rhodamine B-conjugated encrypted vipericidin nonapeptide is a potent toxin to zebrafish and associated with in vitro 
cytotoxicity. Biochim. Biophys. Acta 1850, 1253–1260, https://doi.org/10.1016/j.bbagen.2015.02.013 (2015).
Acknowledgements
This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq); 
the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES); the Fundação de Apoio ao 
Desenvolvimento do Ensino, Ciência e Tecnologia do Estado do Mato Grosso do Sul (FUNDECT); the Fundação 
de Apoio à Pesquisa do Distrito Federal (FAPDF); Dutch Polymer Institute (DPI) and the EU (H2020 project 
AND 659–121) and the Dutch Organization for Scientific Research NWO (ZonMw grant 541001008).
Author contributions
R.d.V. and O.L.F. obtained funding. Antimicrobial activity assays were designed by N.G.J.O. and J.M.W. and 
carried out by N.G.J.O. Toxicity assays were designed by T.M.B.R. and N.G.J.O. and carried out by N.G.J.O. and 
N.V. Circular Dichroism experiments were designed, performed and analyzed by N.G.J.O. and R.d.V. Microscopy 
experiments were designed and carried out by M.G. and N.G.J.O. Molecular Dynamics simulations were designed 
and performed by N.G.J.O. and M.H.C., N.G.J.O. wrote the manuscript. All authors reviewed the manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-66164-w.
Correspondence and requests for materials should be addressed to O.L.F.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
